Bio-Rad Laboratories, Inc. (BIO)Healthcare | Medical Devices | Hercules, United States | NYSE
363.73 USD
-0.69
(-0.189%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 356.46 -7.27 (-7.270%) ⇩ (Oct. 13, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 11:13 a.m. EDT
The investment case here is severely compromised by a brutal multi-year price trajectory. Despite the company's niche position in medical devices, the stock has endured four consecutive years of negative annual returns, dragging the total performance down despite a positive cumulative gain over the full nine-year window. This persistent decline signals that the market views the current valuation as unjustified given the lack of recent growth momentum. Compounding this fundamental weakness is the complete absence of a dividend program, offering no income buffer during this stagnation. While activist interest and new product launches provide a glimmer of hope, the technical picture remains bleak with the price trading well below its 200-day average, and options flow confirms a defensive posture among traders. The statistical forecast offers only a weak lean upward, insufficient to counteract the structural damage inflicted by years of underperformance. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.150981 |
| AutoETS | 0.151083 |
| MSTL | 0.159042 |
| AutoARIMA | 0.203641 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 3.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.044 |
| Excess Kurtosis | -0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.103 |
| Revenue per Share | 96.197 |
| Market Cap | 9,733,996,544 |
| Trailing P/E | 46.10 |
| Forward P/E | 36.68 |
| Beta | 1.07 |
| Profit Margins | 8.59% |
| Website | https://www.bio-rad.com |
As of Oct. 10, 2026, 11:13 a.m. EDT: Speculators are positioning defensively with heavy put volume at strikes significantly below the current price (deep OTM), while call activity is sparse and concentrated near the money. The implied volatility skew shows elevated premiums for downside protection compared to upside speculation, suggesting a market consensus focused on avoiding further losses rather than anticipating a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19149911 |
| Address1 | 1,000 Alfred Nobel Drive |
| All Time High | 832.7 |
| All Time Low | 0.851852 |
| Ask | 0.0 |
| Ask Size | 240 |
| Audit Risk | 4 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 230,410 |
| Average Daily Volume3 Month | 275,519 |
| Average Volume | 275,519 |
| Average Volume10Days | 230,410 |
| Beta | 1.068 |
| Bid | 0.0 |
| Bid Size | 80 |
| Board Risk | 9 |
| Book Value | 268.303 |
| City | Hercules |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 363.73 |
| Current Ratio | 3.142 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 366.24 |
| Day Low | 358.425 |
| Debt To Equity | 19.103 |
| Display Name | Bio-Rad Laboratories |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,877,200 |
| Earnings Call Timestamp Start | 1,785,877,200 |
| Earnings Growth | 0.187 |
| Earnings Quarterly Growth | 0.169 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,304,000 |
| Earnings Timestamp Start | 1,793,304,000 |
| Ebitda | 441,000,000 |
| Ebitda Margins | 0.17031999 |
| Enterprise To Ebitda | 21.491 |
| Enterprise To Revenue | 3.66 |
| Enterprise Value | 9,477,376,000 |
| Eps Current Year | 9.45 |
| Eps Forward | 9.91667 |
| Eps Trailing Twelve Months | 7.89 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 510 741 5817 |
| Fifty Day Average | 370.9682 |
| Fifty Day Average Change | -7.2381897 |
| Fifty Day Average Change Percent | -0.019511618 |
| Fifty Two Week Change Percent | 19.149912 |
| Fifty Two Week High | 396.23 |
| Fifty Two Week High Change | -32.5 |
| Fifty Two Week High Change Percent | -0.08202306 |
| Fifty Two Week Low | 236.73 |
| Fifty Two Week Low Change | 127.000015 |
| Fifty Two Week Low Change Percent | 0.53647625 |
| Fifty Two Week Range | 236.73 - 396.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 320,509,800,000 |
| Float Shares | 21,352,572 |
| Forward Eps | 9.91667 |
| Forward P E | 36.678646 |
| Free Cashflow | 283,187,488 |
| Full Exchange Name | NYSE |
| Full Time Employees | 7,450 |
| Fullday Change | -7.960022 |
| Fullday Change Percent | -2.1842988 |
| Fullday Price | 363.73 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.52041 |
| Gross Profits | 1,347,500,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16406 |
| Held Percent Institutions | 0.91602 |
| Implied Shares Outstanding | 26,761,598 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,015,545,600 |
| Last Split Factor | 2:1 |
| Long Business Summary | Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. |
| Long Name | Bio-Rad Laboratories, Inc. |
| Market | us_market |
| Market Cap | 9,733,996,544 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_255743 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 222,400,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,060,717,419 |
| Number Of Analyst Opinions | 3 |
| Open | 369.0 |
| Operating Cashflow | 492,600,000 |
| Operating Margins | 0.111829996 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.01 |
| Phone | 510 724 7000 |
| Post Market Change | -7.2700195 |
| Post Market Change Percent | -1.9987407 |
| Post Market Price | 356.46 |
| Post Market Time | 1,791,934,204 |
| Previous Close | 364.42 |
| Price Eps Current Year | 38.48995 |
| Price Hint | 2 |
| Price To Book | 1.3556688 |
| Price To Sales Trailing12 Months | 3.759316 |
| Profit Margins | 0.085889995 |
| Quick Ratio | 2.153 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | -0.690002 |
| Regular Market Change Percent | -0.189343 |
| Regular Market Day High | 366.24 |
| Regular Market Day Low | 358.425 |
| Regular Market Day Range | 358.425 - 366.24 |
| Regular Market Open | 369.0 |
| Regular Market Previous Close | 364.42 |
| Regular Market Price | 363.73 |
| Regular Market Time | 1,791,921,602 |
| Regular Market Volume | 132,588 |
| Return On Assets | 0.01663 |
| Return On Equity | 0.0311 |
| Revenue Growth | -0.001 |
| Revenue Per Share | 96.197 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 21,700,560 |
| Shares Percent Shares Out | 0.0442 |
| Shares Short | 1,182,765 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 1,130,298 |
| Short Name | Bio-Rad Laboratories, Inc. |
| Short Percent Of Float | 0.0744 |
| Short Ratio | 4.37 |
| Source Interval | 15 |
| State | CA |
| Symbol | BIO |
| Target High Price | 390.0 |
| Target Low Price | 280.0 |
| Target Mean Price | 328.33334 |
| Target Median Price | 315.0 |
| Total Cash | 1,618,499,968 |
| Total Cash Per Share | 60.531 |
| Total Debt | 1,370,400,000 |
| Total Revenue | 2,589,299,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 7.89 |
| Trailing P E | 46.10013 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 309.7075 |
| Two Hundred Day Average Change | 54.022522 |
| Two Hundred Day Average Change Percent | 0.17443079 |
| Type Disp | Equity |
| Volume | 132,588 |
| Website | https://www.bio-rad.com |
| Zip | 94,547 |